# Cemag Invest

> Cemag Invest is a VC fund in Paris backing Medical and Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 12
- Last investment: Jun 2026
- Lead investor: 25%
- Last updated: Aug 2026

Cemag Invest is a family office founded in 2016 dedicated to minority capital development investments in the fields of healthcare, B to B services, and technology.

## Contacts

5 contacts available for Cemag Invest. Shizune tracks 1 team members at Cemag Invest. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cemag-invest?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.5M–$11M |
| Series B | $7.7M–$34M |
| Private Equity | $18M–$18M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 25% |
| Health Care | 3 | 25% |
| Artificial Intelligence | 3 | 25% |
| Manufacturing | 2 | 17% |
| Medical Device | 2 | 17% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 25% |
| Series A | 2 | 17% |
| Private Equity | 2 | 17% |
| Seed | 1 | 8% |
| Series C | 1 | 8% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Catherine Dunand | President and Founder | 5 | https://shizune.co/investors/profile/catherine-dunand |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $1.7M | Post-IPO Debt | Jun 22, 2026 |  |
| Wandercraft | Wandercraft develops autonomous walking exoskeletons and robotic systems designed to restore upright mobility to individuals with walking impairments. The company offers devices such as Atalante X, a hands‑free, self‑balancing exoskeleton used in rehabilitation centers, and a Personal Exoskeleton prototype that leverages AI‑driven balance tosupport walking in daily life. Their systems incorporate real‑time adaptive gait algorithms and powered joints to facilitate multidirectional movement and support early intensive rehabilitation. Wandercraft collaborates with healthcare institutions and has initiated clinical trials to evaluate safety and effectiveness in managing spinal cord injuries and stroke rehabilitation. | $75M | Series D | Jun 06, 2025 |  |
| Diabeloop | Diabeloop is a medical device company for diabetes and closed-loop system. It also develops disruptive technological innovations to automate the treatment of diabetes.The company mission is to make accessible disruptive technological innovations that will allow people with type 1 diabetes to live the life they want. Diabeloop was founded in 2015and is headquartered in Grenoble, Auvergne-Rhône-Alpes, France. | $16.3M | Venture - Series Unknown | Mar 04, 2024 |  |
| Oso | Oso is a business that focuses on ambient intelligence for careers and persons in vulnerable situations. Oso is healthcare and well-being from human noises. | $11M | Series A | Apr 20, 2023 |  |
| Avicenna.ai | Avicenna.ai is an innovative medical device company. Avicenna.ai develops new generation of algorithms dedicated to the detection of life threatening lesions. | $7.5M | Series A | Feb 08, 2023 |  |
| Wandercraft | Wandercraft develops autonomous walking exoskeletons and robotic systems designed to restore upright mobility to individuals with walking impairments. The company offers devices such as Atalante X, a hands‑free, self‑balancing exoskeleton used in rehabilitation centers, and a Personal Exoskeleton prototype that leverages AI‑driven balance tosupport walking in daily life. Their systems incorporate real‑time adaptive gait algorithms and powered joints to facilitate multidirectional movement and support early intensive rehabilitation. Wandercraft collaborates with healthcare institutions and has initiated clinical trials to evaluate safety and effectiveness in managing spinal cord injuries and stroke rehabilitation. | $45.3M | Series C | Jan 20, 2022 |  |
| Aryballe Technologies | Aryballe Technologies was created in Grenoble/France by a team of scientists and entrepreneurs. As a technology platform their main objectives are to develop new generations of universal sensors which can be adapted to different applications.In parallel to their core hardware development activities they are also organized to handle thesoftware + database development and full manufacturing of their sensors and devices. | $7.9M | Series B | Jul 10, 2020 |  |
| Avicenna.ai | Avicenna.ai is an innovative medical device company. Avicenna.ai develops new generation of algorithms dedicated to the detection of life threatening lesions. | $3M | Seed | Feb 07, 2020 |  |
| Diabeloop | Diabeloop is a medical device company for diabetes and closed-loop system. It also develops disruptive technological innovations to automate the treatment of diabetes.The company mission is to make accessible disruptive technological innovations that will allow people with type 1 diabetes to live the life they want. Diabeloop was founded in 2015and is headquartered in Grenoble, Auvergne-Rhône-Alpes, France. | $34M | Series B | Dec 02, 2019 |  |
| Wandercraft | Wandercraft develops autonomous walking exoskeletons and robotic systems designed to restore upright mobility to individuals with walking impairments. The company offers devices such as Atalante X, a hands‑free, self‑balancing exoskeleton used in rehabilitation centers, and a Personal Exoskeleton prototype that leverages AI‑driven balance tosupport walking in daily life. Their systems incorporate real‑time adaptive gait algorithms and powered joints to facilitate multidirectional movement and support early intensive rehabilitation. Wandercraft collaborates with healthcare institutions and has initiated clinical trials to evaluate safety and effectiveness in managing spinal cord injuries and stroke rehabilitation. | $25M | Series B | Oct 11, 2017 |  |

10 of 12 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 5 deals together
- [Innovacom](https://shizune.co/investors/profile/innovacom) — VC Fund, 5 deals together
- [LBO France](https://shizune.co/investors/profile/lbo-france) — VC Fund, 3 deals together
- [InnoBio](https://shizune.co/investors/profile/innobio) — VC Fund, 2 deals together
- [IRDI SORIDEC Gestion](https://shizune.co/investors/profile/irdi-soridec-gestion) — VC Fund, 2 deals together
- [IXO Private Equity](https://shizune.co/investors/profile/ixo-private-equity) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Medical VC Funds in France](https://shizune.co/investors/medical-vc-funds-france)
- [Medical Investors in France](https://shizune.co/investors/medical-investors-france)

## FAQ

### What does Cemag Invest invest in?

Cemag Invest invests primarily in Medical, Health Care and Artificial Intelligence startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Cemag Invest's check size?

Cemag Invest typically joins rounds of $7.5M–$11M at Series A, $7.7M–$34M at Series B and $18M–$18M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cemag Invest participates in.

### How do I contact Cemag Invest?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cemag Invest?

The team at Cemag Invest includes Catherine Dunand (President and Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co